Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
Behav Brain Res ; 462: 114886, 2024 Mar 28.
Article in English | MEDLINE | ID: mdl-38309373

ABSTRACT

Celiac disease (CD) is an immune-mediated disease affecting the small intestine. The only treatment strategy for CD is the gluten-free diet (GFD). One of the more common mental disorders in CD patients is major depressive disorder (MDD). The influence of GFD on the occurrence of MDD symptoms in patients with CD will be evaluated. This diet often reduces nutritional deficiencies in these patients and also helps to reduce depressive symptoms. Both disease entities are often dominated by the same deficiencies of nutrients such as iron, zinc, selenium, iodine, or B and D vitamins. Deficiencies of particular components in CD can favor MDD and vice versa. Gluten can adversely affect the mental state of patients without CD. Also, intestinal microbiota may play an important role in the described process. This work aims to comprehensively assess the common factors involved in the pathomechanisms of MDD and CD, with particular emphasis on nutrient imbalances. Given the complexity of both disease entities, and the many common links, more research related to improving mental health in these patients and the implementation of a GFD would need to be conducted, but it appears to be a viable pathway to improving the quality of life and health of people struggling with CD and MDD. Therefore, probiotics, micronutrients, macronutrients, and vitamin supplements are recommended to reduce the risk of MDD, given that they may alleviate the symptoms of both these disease entities. In turn, in patients with MDD, it is worth considering testing for CD.


Subject(s)
Celiac Disease , Depressive Disorder, Major , Malnutrition , Humans , Celiac Disease/complications , Celiac Disease/diagnosis , Quality of Life , Diet, Gluten-Free
2.
Int J Mol Sci ; 23(18)2022 Sep 13.
Article in English | MEDLINE | ID: mdl-36142523

ABSTRACT

Schizophrenia and depression are heterogeneous disorders. The complex pathomechanism of the diseases imply that medication responses vary across patients. Many psychotropic drugs are available but achieving optimal therapeutic effect can be challenging. The evidence correlates well with clinical observations, suggesting that new atypical antipsychotic drugs are effective against negative and cognitive symptoms of schizophrenia, as well as against affective symptoms observed in depression. The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. We have first provided a brief overview of the major neurobiological underpinnings of schizophrenia and depression. We then shortly discuss efficacy, safety and limitations of ongoing pharmacotherapy used in depression and schizophrenia. Mainly, we have focused this review on the therapeutic potential of new atypical antipsychotic drugs-currently existing-to be effective in psychotic, as well as in affective disorders.


Subject(s)
Antipsychotic Agents , Schizophrenia , Antipsychotic Agents/therapeutic use , Aripiprazole/therapeutic use , Depression/drug therapy , Humans , Lurasidone Hydrochloride , Psychotropic Drugs/therapeutic use , Schizophrenia/chemically induced , Schizophrenia/drug therapy
3.
Brain Sci ; 11(10)2021 Sep 30.
Article in English | MEDLINE | ID: mdl-34679364

ABSTRACT

The hypothalamic-pituitary-adrenal (HPA) axis is involved in the pathophysiology of many neuropsychiatric disorders. Increased HPA axis activity can be observed during chronic stress, which plays a key role in the pathophysiology of depression. Overactivity of the HPA axis occurs in major depressive disorder (MDD), leading to cognitive dysfunction and reduced mood. There is also a correlation between the HPA axis activation and gut microbiota, which has a significant impact on the development of MDD. It is believed that the gut microbiota can influence the HPA axis function through the activity of cytokines, prostaglandins, or bacterial antigens of various microbial species. The activity of the HPA axis in schizophrenia varies and depends mainly on the severity of the disease. This review summarizes the involvement of the HPA axis in the pathogenesis of neuropsychiatric disorders, focusing on major depression and schizophrenia, and highlights a possible correlation between these conditions. Although many effective antidepressants are available, a large proportion of patients do not respond to initial treatment. This review also discusses new therapeutic strategies that affect the HPA axis, such as glucocorticoid receptor (GR) antagonists, vasopressin V1B receptor antagonists and non-psychoactive CB1 receptor agonists in depression and/or schizophrenia.

4.
Antioxidants (Basel) ; 10(9)2021 Sep 09.
Article in English | MEDLINE | ID: mdl-34573069

ABSTRACT

There is a growing body of scientific research showing the link between depression and dementia in Alzheimer's disease (AD). The chronic stress contributes to the formation of oxidative stress in the parts of the brain involved in the development of depression and AD. The scientific literature reports the significant role of antioxidants, which are highly effective in treating these diseases. In this review, we have summarized the relationship between chronic stress, oxidative stress, and the changes in the brain they cause occurring in the brain. Among all the compounds showing antioxidant properties, the most promising results in AD treatment were observed for Vitamin E, coenzyme Q10 (CoQ10), melatonin, polyphenols, curcumin, and selenium. In case of depression treatment, the greatest potential was observed in curcumin, zinc, selenium, vitamin E, and saffron.

6.
PLoS One ; 10(8): e0135141, 2015.
Article in English | MEDLINE | ID: mdl-26252948

ABSTRACT

Human epithelial, endothelial and PMA-differentiated THP-1 cell lines were used as model systems to study the transcriptional regulation of the human FCGRT gene encoding the alpha chain of hFcRn. The data obtained from site-directed mutagenesis in transient transfection experiments indicate that the Sp1 sites at positions -641, -635, and -313, CF1/YY1 elements at positions -586 and -357, and the AP-1 motif at -276 within the-660/-233 fragment of the human FCGRT promoter (hFCGRT) participate in the regulation of human FCGRT in all selected cell lines. However, their individual contribution to promoter activity is not equivalent. The Sp1 binding site at -313 and the AP-1 site at -276 are critical for the activity of the hFCGRT promoter in epithelial and endothelial cells. Moreover, the CF1/YY1 site at -586 in differentiated THP-1 cells, plays an essential role in the transcriptional activity of the promoter. In addition, the C/EBPbeta binding site at -497 of the hFCGRT promoter in epithelial and endothelial cells, and the C/EBPbeta motif located at -497 and -233 within the hFCGRT promoter in differentiated THP-1 cells may function as positive regulatory sequences in response to LPS or PMA stimulation. EMSA and supershift analyses showed that the functionally identified binding motifs in the hFCGRT promoter were able to specifically interact with their corresponding (Sp1, Sp2, Sp3, c-Fos, c-Jun, YY1, and C/EBPbeta or C/EBPdelta) transcription factors (TFs), suggesting their possible involvement in the regulation of the human FCGRT gene expression.


Subject(s)
Gene Expression Regulation , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/metabolism , Receptors, Fc/genetics , Receptors, Fc/metabolism , Response Elements , Amino Acid Motifs , Binding Sites , CCAAT-Enhancer-Binding Protein-beta/metabolism , Caco-2 Cells , Cell Line, Tumor , Cell Nucleus/metabolism , Endothelial Cells/cytology , Epithelial Cells/cytology , HL-60 Cells , Human Umbilical Vein Endothelial Cells , Humans , Luciferases/metabolism , Mutagenesis, Site-Directed , Mutation , Oligonucleotides/genetics , Promoter Regions, Genetic , RNA, Messenger/metabolism , Sp1 Transcription Factor , Transcription Factors/metabolism , Transcription, Genetic
8.
Immunopharmacol Immunotoxicol ; 25(4): 645-54, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14686804

ABSTRACT

A proline-rich polypeptide complex (PRP) isolated from ovine colostrum shows immunoregulatory activity. Similar activity was observed when PRP was replaced with a nonapeptide (NP) isolated from chymotryptic digest of PRP. The polypeptide complex also shows procognitive activity. In the form of orally administered tablets called Colostrinin, containing 100 microg of PRP, it improves the outcome of Alzheimer's disease (AD) patients. The mechanism of action of PRP/Colostrinin in AD is not yet clarified. Microglial cells involvement in AD has been related to amyloid beta (Abeta) internalization, the release of inflammatory cytokines, overproduction of nitrogen oxide (NO) and superoxide anion (O2-), and the development of neuritic plaques. It has been previously found in our laboratory that PRP regulates the secretion of an array of cytokines. It also was shown, in preliminary experiments using human blood cells and murine macrophages, that PRP inhibits production of NO and O2- induced by LPS. In the present work, to study the effect of PRP and NP on the release of NO and O2-induced by LPS we applied THP-1 cells. The human monocyte/macrophage THP-1 cell line has been widely used as a model of human microglial cells. The results obtained showed that THP-1 cells release NO when activated with LPS. However, neither PRP nor NP induced production of NO. Although the nonapeptide, at higher concentration (100 microg/mL), showed an inhibitory activity on the release of NO induced by LPS, no inhibition was observed when PRP was used. THP-1 cells treated with LPS, PRP or NP did not release O2-.


Subject(s)
Colostrum/chemistry , Colostrum/immunology , Nitric Oxide/biosynthesis , Peptides/pharmacology , Adjuvants, Immunologic/isolation & purification , Adjuvants, Immunologic/pharmacology , Alzheimer Disease/drug therapy , Amino Acid Sequence , Animals , Cell Line , Female , Humans , Lipopolysaccharides/pharmacology , Mice , Microglia/drug effects , Microglia/metabolism , Peptide Fragments/chemistry , Peptide Fragments/pharmacology , Peptides/isolation & purification , Proline-Rich Protein Domains , Sheep
9.
Postepy Hig Med Dosw ; 57(6): 649-67, 2003.
Article in Polish | MEDLINE | ID: mdl-15002162

ABSTRACT

This review summarizes the status of our knowledge on the structure, expression and function of CD1 proteins. An endosomal and non-endosomal pathways of CD1 antigen presentation are also described.


Subject(s)
Antigen Presentation/physiology , Antigens, CD1 , Endosomes/metabolism , Lipids/immunology , Animals , Antigens, CD1/genetics , Antigens, CD1/immunology , Antigens, CD1/metabolism , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...